nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.121	0.282	CbGbCtD
Alfuzosin—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.082	0.19	CbGbCtD
Alfuzosin—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0783	0.182	CbGbCtD
Alfuzosin—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0698	0.162	CbGbCtD
Alfuzosin—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0409	0.0949	CbGbCtD
Alfuzosin—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0387	0.0897	CbGbCtD
Alfuzosin—Prazosin—CYP1A1—chronic obstructive pulmonary disease	0.00321	1	CrCbGaD
Alfuzosin—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00279	0.0404	CbGpPWpGaD
Alfuzosin—ADRA1A—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.00254	0.0368	CbGpPWpGaD
Alfuzosin—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00141	0.0205	CbGpPWpGaD
Alfuzosin—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00126	0.00254	CcSEcCtD
Alfuzosin—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00126	0.00253	CcSEcCtD
Alfuzosin—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.00126	0.00253	CcSEcCtD
Alfuzosin—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00125	0.00252	CcSEcCtD
Alfuzosin—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00252	CcSEcCtD
Alfuzosin—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00252	CcSEcCtD
Alfuzosin—Mental disorder—Arformoterol—chronic obstructive pulmonary disease	0.00125	0.00252	CcSEcCtD
Alfuzosin—Mental disorder—Formoterol—chronic obstructive pulmonary disease	0.00125	0.00252	CcSEcCtD
Alfuzosin—Infection—Tiotropium—chronic obstructive pulmonary disease	0.00125	0.00251	CcSEcCtD
Alfuzosin—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.00125	0.00251	CcSEcCtD
Alfuzosin—Shock—Tiotropium—chronic obstructive pulmonary disease	0.00124	0.00249	CcSEcCtD
Alfuzosin—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.00123	0.00248	CcSEcCtD
Alfuzosin—Arthropathy—Prednisone—chronic obstructive pulmonary disease	0.00123	0.00248	CcSEcCtD
Alfuzosin—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.00123	0.00247	CcSEcCtD
Alfuzosin—Mental disorder—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00247	CcSEcCtD
Alfuzosin—Angiopathy—Salbutamol—chronic obstructive pulmonary disease	0.00122	0.00246	CcSEcCtD
Alfuzosin—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.00122	0.00246	CcSEcCtD
Alfuzosin—ADRA1D—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.00122	0.0176	CbGpPWpGaD
Alfuzosin—Injury—Prednisolone—chronic obstructive pulmonary disease	0.00122	0.00245	CcSEcCtD
Alfuzosin—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00121	0.00245	CcSEcCtD
Alfuzosin—Back pain—Formoterol—chronic obstructive pulmonary disease	0.0012	0.00242	CcSEcCtD
Alfuzosin—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.0012	0.00242	CcSEcCtD
Alfuzosin—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00119	0.00239	CcSEcCtD
Alfuzosin—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	0.00118	0.00238	CcSEcCtD
Alfuzosin—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00117	0.00236	CcSEcCtD
Alfuzosin—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.00115	0.00232	CcSEcCtD
Alfuzosin—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.00115	0.00232	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00114	0.00231	CcSEcCtD
Alfuzosin—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00229	CcSEcCtD
Alfuzosin—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00229	CcSEcCtD
Alfuzosin—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.00114	0.00229	CcSEcCtD
Alfuzosin—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.00112	0.00226	CcSEcCtD
Alfuzosin—Malaise—Formoterol—chronic obstructive pulmonary disease	0.00112	0.00226	CcSEcCtD
Alfuzosin—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.00112	0.00225	CcSEcCtD
Alfuzosin—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00111	0.00224	CcSEcCtD
Alfuzosin—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.00111	0.00223	CcSEcCtD
Alfuzosin—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.0011	0.00221	CcSEcCtD
Alfuzosin—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.0011	0.00221	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00109	0.00219	CcSEcCtD
Alfuzosin—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00109	0.00219	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00108	0.00218	CcSEcCtD
Alfuzosin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.00108	0.0157	CbGpPWpGaD
Alfuzosin—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00108	0.00217	CcSEcCtD
Alfuzosin—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00107	0.00216	CcSEcCtD
Alfuzosin—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00216	CcSEcCtD
Alfuzosin—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00106	0.00213	CcSEcCtD
Alfuzosin—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00106	0.00213	CcSEcCtD
Alfuzosin—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00106	0.00213	CcSEcCtD
Alfuzosin—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00106	0.00213	CcSEcCtD
Alfuzosin—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00106	0.00213	CcSEcCtD
Alfuzosin—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00106	0.00213	CcSEcCtD
Alfuzosin—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00212	CcSEcCtD
Alfuzosin—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00105	0.00212	CcSEcCtD
Alfuzosin—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00212	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00105	0.00212	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00105	0.00212	CcSEcCtD
Alfuzosin—Neuropathy—Prednisone—chronic obstructive pulmonary disease	0.00105	0.00211	CcSEcCtD
Alfuzosin—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00105	0.0021	CcSEcCtD
Alfuzosin—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00105	0.0021	CcSEcCtD
Alfuzosin—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00209	CcSEcCtD
Alfuzosin—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00104	0.00209	CcSEcCtD
Alfuzosin—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00208	CcSEcCtD
Alfuzosin—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00208	CcSEcCtD
Alfuzosin—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00103	0.00208	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00103	0.00207	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00103	0.00207	CcSEcCtD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.00102	0.0148	CbGpPWpGaD
Alfuzosin—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00101	0.00204	CcSEcCtD
Alfuzosin—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00101	0.00204	CcSEcCtD
Alfuzosin—ADRA1B—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.00101	0.0146	CbGpPWpGaD
Alfuzosin—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00101	0.00203	CcSEcCtD
Alfuzosin—Infection—Formoterol—chronic obstructive pulmonary disease	0.00101	0.00203	CcSEcCtD
Alfuzosin—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000999	0.00201	CcSEcCtD
Alfuzosin—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000999	0.00201	CcSEcCtD
Alfuzosin—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000998	0.00201	CcSEcCtD
Alfuzosin—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000995	0.002	CcSEcCtD
Alfuzosin—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000995	0.002	CcSEcCtD
Alfuzosin—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000993	0.002	CcSEcCtD
Alfuzosin—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000993	0.002	CcSEcCtD
Alfuzosin—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00099	0.00199	CcSEcCtD
Alfuzosin—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00099	0.00199	CcSEcCtD
Alfuzosin—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000987	0.00199	CcSEcCtD
Alfuzosin—Infection—Montelukast—chronic obstructive pulmonary disease	0.000987	0.00199	CcSEcCtD
Alfuzosin—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000985	0.00198	CcSEcCtD
Alfuzosin—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000985	0.00198	CcSEcCtD
Alfuzosin—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000977	0.00197	CcSEcCtD
Alfuzosin—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000974	0.00196	CcSEcCtD
Alfuzosin—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000973	0.00196	CcSEcCtD
Alfuzosin—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000965	0.00194	CcSEcCtD
Alfuzosin—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000958	0.00193	CcSEcCtD
Alfuzosin—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000951	0.00192	CcSEcCtD
Alfuzosin—ADRA1D—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000951	0.0138	CbGpPWpGaD
Alfuzosin—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000948	0.00191	CcSEcCtD
Alfuzosin—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000948	0.00191	CcSEcCtD
Alfuzosin—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000943	0.0019	CcSEcCtD
Alfuzosin—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000942	0.0019	CcSEcCtD
Alfuzosin—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000939	0.00189	CcSEcCtD
Alfuzosin—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000935	0.00188	CcSEcCtD
Alfuzosin—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00093	0.00187	CcSEcCtD
Alfuzosin—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000926	0.00186	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000924	0.00186	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000924	0.00186	CcSEcCtD
Alfuzosin—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000912	0.00184	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000905	0.00182	CcSEcCtD
Alfuzosin—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000902	0.00182	CcSEcCtD
Alfuzosin—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000902	0.00182	CcSEcCtD
Alfuzosin—ADRA1A—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000897	0.013	CbGpPWpGaD
Alfuzosin—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000895	0.0018	CcSEcCtD
Alfuzosin—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000893	0.0018	CcSEcCtD
Alfuzosin—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000893	0.0018	CcSEcCtD
Alfuzosin—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000889	0.00179	CcSEcCtD
Alfuzosin—Injury—Prednisone—chronic obstructive pulmonary disease	0.000884	0.00178	CcSEcCtD
Alfuzosin—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000883	0.00178	CcSEcCtD
Alfuzosin—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000881	0.00177	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000876	0.00176	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000876	0.00176	CcSEcCtD
Alfuzosin—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000874	0.00176	CcSEcCtD
Alfuzosin—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000874	0.00176	CcSEcCtD
Alfuzosin—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000874	0.00176	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000873	0.00176	CcSEcCtD
Alfuzosin—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000867	0.00175	CcSEcCtD
Alfuzosin—Pain—Formoterol—chronic obstructive pulmonary disease	0.000867	0.00175	CcSEcCtD
Alfuzosin—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000867	0.00175	CcSEcCtD
Alfuzosin—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000867	0.00175	CcSEcCtD
Alfuzosin—ADRA1D—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	0.000861	0.0125	CbGpPWpGaD
Alfuzosin—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000858	0.00173	CcSEcCtD
Alfuzosin—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000856	0.00172	CcSEcCtD
Alfuzosin—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000851	0.00171	CcSEcCtD
Alfuzosin—Pain—Montelukast—chronic obstructive pulmonary disease	0.00085	0.00171	CcSEcCtD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000849	0.0123	CbGpPWpGaD
Alfuzosin—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000847	0.00171	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000844	0.0017	CcSEcCtD
Alfuzosin—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000843	0.0017	CcSEcCtD
Alfuzosin—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000841	0.0122	CbGpPWpGaD
Alfuzosin—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00084	0.00169	CcSEcCtD
Alfuzosin—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000839	0.00169	CcSEcCtD
Alfuzosin—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000836	0.00168	CcSEcCtD
Alfuzosin—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000836	0.00168	CcSEcCtD
Alfuzosin—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000835	0.00168	CcSEcCtD
Alfuzosin—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000831	0.00167	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000829	0.00167	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000829	0.00167	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000827	0.00166	CcSEcCtD
Alfuzosin—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000826	0.00166	CcSEcCtD
Alfuzosin—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000819	0.00165	CcSEcCtD
Alfuzosin—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000819	0.00165	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000812	0.00164	CcSEcCtD
Alfuzosin—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.000812	0.00164	CcSEcCtD
Alfuzosin—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000806	0.00162	CcSEcCtD
Alfuzosin—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000806	0.00162	CcSEcCtD
Alfuzosin—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000802	0.00161	CcSEcCtD
Alfuzosin—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000802	0.00161	CcSEcCtD
Alfuzosin—ADRA1A—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	0.000801	0.0116	CbGpPWpGaD
Alfuzosin—ADRA1D—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000799	0.0116	CbGpPWpGaD
Alfuzosin—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000799	0.00161	CcSEcCtD
Alfuzosin—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000792	0.0016	CcSEcCtD
Alfuzosin—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000792	0.00159	CcSEcCtD
Alfuzosin—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000792	0.00159	CcSEcCtD
Alfuzosin—ADRA1B—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000789	0.0114	CbGpPWpGaD
Alfuzosin—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000789	0.00159	CcSEcCtD
Alfuzosin—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000789	0.00159	CcSEcCtD
Alfuzosin—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000787	0.00159	CcSEcCtD
Alfuzosin—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000785	0.00158	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000783	0.00158	CcSEcCtD
Alfuzosin—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000761	0.00153	CcSEcCtD
Alfuzosin—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000757	0.00152	CcSEcCtD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000754	0.0109	CbGpPWpGaD
Alfuzosin—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000746	0.0015	CcSEcCtD
Alfuzosin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.00073	0.0106	CbGpPWpGaD
Alfuzosin—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000728	0.00147	CcSEcCtD
Alfuzosin—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000728	0.00147	CcSEcCtD
Alfuzosin—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000718	0.00144	CcSEcCtD
Alfuzosin—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000718	0.00144	CcSEcCtD
Alfuzosin—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000713	0.00144	CcSEcCtD
Alfuzosin—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000703	0.00142	CcSEcCtD
Alfuzosin—ADRA1A—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000701	0.0102	CbGpPWpGaD
Alfuzosin—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000694	0.0014	CcSEcCtD
Alfuzosin—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000694	0.0014	CcSEcCtD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000689	0.00999	CbGpPWpGaD
Alfuzosin—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000687	0.00138	CcSEcCtD
Alfuzosin—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.00068	0.00137	CcSEcCtD
Alfuzosin—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000678	0.00136	CcSEcCtD
Alfuzosin—KCNH2—Hematopoietic Stem Cell Differentiation—IL1B—chronic obstructive pulmonary disease	0.000671	0.00973	CbGpPWpGaD
Alfuzosin—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000671	0.00135	CcSEcCtD
Alfuzosin—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000671	0.00135	CcSEcCtD
Alfuzosin—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000664	0.00963	CbGpPWpGaD
Alfuzosin—ADRA1B—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000663	0.00962	CbGpPWpGaD
Alfuzosin—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000657	0.00132	CcSEcCtD
Alfuzosin—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000655	0.00132	CcSEcCtD
Alfuzosin—ADRA1B—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.000655	0.00949	CbGpPWpGaD
Alfuzosin—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000646	0.0013	CcSEcCtD
Alfuzosin—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000645	0.0013	CcSEcCtD
Alfuzosin—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000645	0.0013	CcSEcCtD
Alfuzosin—KCNH2—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.000644	0.00934	CbGpPWpGaD
Alfuzosin—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000639	0.00129	CcSEcCtD
Alfuzosin—Rash—Formoterol—chronic obstructive pulmonary disease	0.000639	0.00129	CcSEcCtD
Alfuzosin—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000639	0.00129	CcSEcCtD
Alfuzosin—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000639	0.00129	CcSEcCtD
Alfuzosin—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000636	0.00923	CbGpPWpGaD
Alfuzosin—Headache—Formoterol—chronic obstructive pulmonary disease	0.000635	0.00128	CcSEcCtD
Alfuzosin—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000635	0.00128	CcSEcCtD
Alfuzosin—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000633	0.00128	CcSEcCtD
Alfuzosin—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000632	0.00127	CcSEcCtD
Alfuzosin—Rash—Montelukast—chronic obstructive pulmonary disease	0.000626	0.00126	CcSEcCtD
Alfuzosin—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000626	0.00126	CcSEcCtD
Alfuzosin—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000624	0.00126	CcSEcCtD
Alfuzosin—Headache—Montelukast—chronic obstructive pulmonary disease	0.000622	0.00125	CcSEcCtD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000622	0.00901	CbGpPWpGaD
Alfuzosin—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000615	0.00124	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	0.000613	0.00124	CcSEcCtD
Alfuzosin—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000611	0.00886	CbGpPWpGaD
Alfuzosin—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000609	0.00123	CcSEcCtD
Alfuzosin—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000607	0.00122	CcSEcCtD
Alfuzosin—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000605	0.00122	CcSEcCtD
Alfuzosin—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000604	0.00122	CcSEcCtD
Alfuzosin—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000604	0.00122	CcSEcCtD
Alfuzosin—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000603	0.00121	CcSEcCtD
Alfuzosin—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000602	0.00121	CcSEcCtD
Alfuzosin—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000602	0.00121	CcSEcCtD
Alfuzosin—Headache—Salbutamol—chronic obstructive pulmonary disease	0.0006	0.00121	CcSEcCtD
Alfuzosin—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000592	0.00119	CcSEcCtD
Alfuzosin—Nausea—Montelukast—chronic obstructive pulmonary disease	0.00059	0.00119	CcSEcCtD
Alfuzosin—ADRA1A—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000589	0.00855	CbGpPWpGaD
Alfuzosin—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000587	0.00852	CbGpPWpGaD
Alfuzosin—ADRA1A—AMPK Signaling—ADIPOQ—chronic obstructive pulmonary disease	0.000582	0.00843	CbGpPWpGaD
Alfuzosin—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000569	0.00115	CcSEcCtD
Alfuzosin—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000566	0.00114	CcSEcCtD
Alfuzosin—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000552	0.00111	CcSEcCtD
Alfuzosin—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000549	0.00111	CcSEcCtD
Alfuzosin—Shock—Prednisolone—chronic obstructive pulmonary disease	0.00054	0.00109	CcSEcCtD
Alfuzosin—ADRA1D—GPCRs, Other—ADRB2—chronic obstructive pulmonary disease	0.00054	0.00783	CbGpPWpGaD
Alfuzosin—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000536	0.00108	CcSEcCtD
Alfuzosin—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000531	0.00107	CcSEcCtD
Alfuzosin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00053	0.00769	CbGpPWpGaD
Alfuzosin—KCNH2—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000525	0.00762	CbGpPWpGaD
Alfuzosin—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000525	0.00106	CcSEcCtD
Alfuzosin—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000521	0.00105	CcSEcCtD
Alfuzosin—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.00051	0.00103	CcSEcCtD
Alfuzosin—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000509	0.00738	CbGpPWpGaD
Alfuzosin—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000492	0.000991	CcSEcCtD
Alfuzosin—ADRA1A—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	0.000488	0.00708	CbGpPWpGaD
Alfuzosin—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000483	0.007	CbGpPWpGaD
Alfuzosin—Pain—Prednisolone—chronic obstructive pulmonary disease	0.00047	0.000946	CcSEcCtD
Alfuzosin—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000454	0.000914	CcSEcCtD
Alfuzosin—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000453	0.000911	CcSEcCtD
Alfuzosin—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000447	0.0009	CcSEcCtD
Alfuzosin—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000444	0.00643	CbGpPWpGaD
Alfuzosin—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000441	0.000888	CcSEcCtD
Alfuzosin—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000439	0.000885	CcSEcCtD
Alfuzosin—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000439	0.000883	CcSEcCtD
Alfuzosin—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000436	0.000879	CcSEcCtD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000431	0.00625	CbGpPWpGaD
Alfuzosin—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.00043	0.000865	CcSEcCtD
Alfuzosin—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000427	0.00619	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	0.000422	0.00613	CbGpPWpGaD
Alfuzosin—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000416	0.000838	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000414	0.000833	CcSEcCtD
Alfuzosin—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000411	0.000828	CcSEcCtD
Alfuzosin—ADRA1B—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000407	0.0059	CbGpPWpGaD
Alfuzosin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000399	0.00579	CbGpPWpGaD
Alfuzosin—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000399	0.000804	CcSEcCtD
Alfuzosin—Infection—Prednisone—chronic obstructive pulmonary disease	0.000397	0.000798	CcSEcCtD
Alfuzosin—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—chronic obstructive pulmonary disease	0.000393	0.0057	CbGpPWpGaD
Alfuzosin—Shock—Prednisone—chronic obstructive pulmonary disease	0.000393	0.000791	CcSEcCtD
Alfuzosin—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000391	0.000788	CcSEcCtD
Alfuzosin—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00039	0.000784	CcSEcCtD
Alfuzosin—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000388	0.000781	CcSEcCtD
Alfuzosin—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000386	0.000777	CcSEcCtD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000381	0.00553	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000374	0.00543	CbGpPWpGaD
Alfuzosin—ADRA1D—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000364	0.00528	CbGpPWpGaD
Alfuzosin—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000364	0.000732	CcSEcCtD
Alfuzosin—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000363	0.000731	CcSEcCtD
Alfuzosin—ADRA1A—AMPK Signaling—LEP—chronic obstructive pulmonary disease	0.000361	0.00524	CbGpPWpGaD
Alfuzosin—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000351	0.000707	CcSEcCtD
Alfuzosin—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000346	0.000697	CcSEcCtD
Alfuzosin—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000346	0.000697	CcSEcCtD
Alfuzosin—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000344	0.000693	CcSEcCtD
Alfuzosin—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000344	0.000693	CcSEcCtD
Alfuzosin—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000341	0.000687	CcSEcCtD
Alfuzosin—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000329	0.000662	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000326	0.000657	CcSEcCtD
Alfuzosin—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000326	0.000657	CcSEcCtD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000321	0.00465	CbGpPWpGaD
Alfuzosin—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000317	0.000638	CcSEcCtD
Alfuzosin—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000316	0.000635	CcSEcCtD
Alfuzosin—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000314	0.00455	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000311	0.0045	CbGpPWpGaD
Alfuzosin—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000302	0.00438	CbGpPWpGaD
Alfuzosin—ADRA1B—LPA receptor mediated events—CXCL8—chronic obstructive pulmonary disease	0.000287	0.00416	CbGpPWpGaD
Alfuzosin—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000286	0.000577	CcSEcCtD
Alfuzosin—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000282	0.000569	CcSEcCtD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	0.000276	0.004	CbGpPWpGaD
Alfuzosin—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000273	0.00055	CcSEcCtD
Alfuzosin—ADRA1D—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000271	0.00394	CbGpPWpGaD
Alfuzosin—ADRA1A—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	0.000269	0.00389	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000266	0.00386	CbGpPWpGaD
Alfuzosin—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000264	0.000531	CcSEcCtD
Alfuzosin—ADRA1B—LPA receptor mediated events—MMP9—chronic obstructive pulmonary disease	0.00026	0.00376	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000259	0.00376	CbGpPWpGaD
Alfuzosin—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000254	0.000511	CcSEcCtD
Alfuzosin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000254	0.00368	CbGpPWpGaD
Alfuzosin—Rash—Prednisone—chronic obstructive pulmonary disease	0.000252	0.000507	CcSEcCtD
Alfuzosin—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000251	0.000506	CcSEcCtD
Alfuzosin—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.00025	0.00363	CbGpPWpGaD
Alfuzosin—Headache—Prednisone—chronic obstructive pulmonary disease	0.00025	0.000503	CcSEcCtD
Alfuzosin—ADRA1D—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000244	0.00354	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000243	0.00352	CbGpPWpGaD
Alfuzosin—ADRA1D—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000237	0.00344	CbGpPWpGaD
Alfuzosin—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000237	0.000477	CcSEcCtD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.000236	0.00343	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000236	0.00342	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000235	0.0034	CbGpPWpGaD
Alfuzosin—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000228	0.0033	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000226	0.00328	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.000225	0.00327	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000212	0.00308	CbGpPWpGaD
Alfuzosin—ADRA1B—LPA receptor mediated events—EGFR—chronic obstructive pulmonary disease	0.00021	0.00304	CbGpPWpGaD
Alfuzosin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000206	0.00298	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000203	0.00294	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000201	0.00292	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000201	0.00292	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.0002	0.0029	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.0002	0.0029	CbGpPWpGaD
Alfuzosin—ADRA1B—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000197	0.00286	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000195	0.00283	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000191	0.00277	CbGpPWpGaD
Alfuzosin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00267	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000184	0.00266	CbGpPWpGaD
Alfuzosin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000182	0.00264	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.00018	0.00261	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.00018	0.00261	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.000179	0.00259	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000176	0.00256	CbGpPWpGaD
Alfuzosin—ADRA1A—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.000175	0.00254	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000173	0.00251	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000171	0.00248	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000167	0.00242	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000166	0.00241	CbGpPWpGaD
Alfuzosin—ADRA1B—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.000166	0.00241	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.000164	0.00238	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000157	0.00228	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000157	0.00227	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000155	0.00225	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000153	0.00222	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000152	0.00221	CbGpPWpGaD
Alfuzosin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000149	0.00217	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000149	0.00216	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000148	0.00215	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000147	0.00214	CbGpPWpGaD
Alfuzosin—ADRA1A—AMPK Signaling—TP53—chronic obstructive pulmonary disease	0.000147	0.00214	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000142	0.00206	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000138	0.002	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000137	0.00198	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	0.000135	0.00196	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000133	0.00192	CbGpPWpGaD
Alfuzosin—KCNH2—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	0.000132	0.00192	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000131	0.00191	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.00013	0.00189	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.00013	0.00188	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000129	0.00187	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000127	0.00184	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000126	0.00183	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000125	0.00182	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000121	0.00176	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.00012	0.00174	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000116	0.00168	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000115	0.00166	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000115	0.00166	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000114	0.00165	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000113	0.00164	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000109	0.00158	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	0.000108	0.00156	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000104	0.00151	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.000102	0.00147	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000101	0.00146	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000101	0.00146	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	9.94e-05	0.00144	CbGpPWpGaD
Alfuzosin—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	9.71e-05	0.00141	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	9.59e-05	0.00139	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	9.24e-05	0.00134	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	9.18e-05	0.00133	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	9.11e-05	0.00132	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	8.98e-05	0.0013	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	8.93e-05	0.0013	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	8.83e-05	0.00128	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	8.66e-05	0.00126	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	8.37e-05	0.00121	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	8.26e-05	0.0012	CbGpPWpGaD
Alfuzosin—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	8.06e-05	0.00117	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	7.96e-05	0.00115	CbGpPWpGaD
Alfuzosin—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	7.93e-05	0.00115	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	7.86e-05	0.00114	CbGpPWpGaD
Alfuzosin—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	7.83e-05	0.00113	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	7.73e-05	0.00112	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	7.62e-05	0.00111	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	7.4e-05	0.00107	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	7.4e-05	0.00107	CbGpPWpGaD
Alfuzosin—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	7.37e-05	0.00107	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	7.18e-05	0.00104	CbGpPWpGaD
Alfuzosin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	7.16e-05	0.00104	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	7.07e-05	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	7.02e-05	0.00102	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	6.77e-05	0.000982	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	6.77e-05	0.000981	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	6.52e-05	0.000946	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	6.42e-05	0.000931	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	6.38e-05	0.000926	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	6.38e-05	0.000925	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	6.14e-05	0.000891	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	6.14e-05	0.000891	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	6.14e-05	0.00089	CbGpPWpGaD
Alfuzosin—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	6.12e-05	0.000887	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	5.83e-05	0.000845	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	5.79e-05	0.00084	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	5.7e-05	0.000827	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	5.62e-05	0.000814	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	5.46e-05	0.000791	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	5.45e-05	0.000791	CbGpPWpGaD
Alfuzosin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	5.43e-05	0.000788	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	5.41e-05	0.000785	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	5.18e-05	0.000751	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	5.1e-05	0.000739	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—KL—chronic obstructive pulmonary disease	5.03e-05	0.00073	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	4.99e-05	0.000723	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.64e-05	0.000673	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	4.53e-05	0.000657	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	4.49e-05	0.000651	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.23e-05	0.000613	CbGpPWpGaD
Alfuzosin—ADRA1D—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.18e-05	0.000606	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—KL—chronic obstructive pulmonary disease	4.18e-05	0.000605	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.15e-05	0.000602	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	4.11e-05	0.000596	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	3.99e-05	0.000579	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.85e-05	0.000559	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.82e-05	0.000555	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.8e-05	0.00055	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.77e-05	0.000547	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	3.71e-05	0.000538	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.63e-05	0.000526	CbGpPWpGaD
Alfuzosin—ADRA1B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.47e-05	0.000503	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.44e-05	0.000499	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	3.42e-05	0.000496	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.37e-05	0.000489	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	3.15e-05	0.000457	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	3.13e-05	0.000454	CbGpPWpGaD
Alfuzosin—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	3.08e-05	0.000447	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	3.06e-05	0.000444	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.01e-05	0.000437	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.8e-05	0.000406	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.8e-05	0.000406	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.78e-05	0.000403	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.77e-05	0.000402	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.68e-05	0.000388	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.65e-05	0.000384	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.53e-05	0.000367	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.49e-05	0.000361	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.3e-05	0.000334	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.25e-05	0.000326	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.24e-05	0.000325	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	2.22e-05	0.000322	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.2e-05	0.000319	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.13e-05	0.000309	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.1e-05	0.000304	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.05e-05	0.000297	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.03e-05	0.000294	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	2.03e-05	0.000294	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.95e-05	0.000283	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.87e-05	0.000271	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.86e-05	0.00027	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.86e-05	0.00027	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.82e-05	0.000264	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.77e-05	0.000257	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.68e-05	0.000244	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.67e-05	0.000242	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.65e-05	0.00024	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.64e-05	0.000238	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.57e-05	0.000228	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.56e-05	0.000226	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.54e-05	0.000223	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.51e-05	0.000219	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.5e-05	0.000217	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.43e-05	0.000208	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.39e-05	0.000201	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.38e-05	0.0002	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.36e-05	0.000197	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.36e-05	0.000197	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.34e-05	0.000195	CbGpPWpGaD
Alfuzosin—ADRA1D—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.26e-05	0.000183	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.23e-05	0.000179	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.21e-05	0.000175	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.14e-05	0.000166	CbGpPWpGaD
Alfuzosin—ADRA1B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.05e-05	0.000152	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.01e-05	0.000147	CbGpPWpGaD
Alfuzosin—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	9.29e-06	0.000135	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	9.22e-06	0.000134	CbGpPWpGaD
Alfuzosin—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	8.82e-06	0.000128	CbGpPWpGaD
